Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain NBIX message board posts where the ticker symbol NBIX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest NBIX SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-017715 Size: 9 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-017709 Size: 8 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-017693 Size: 14 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-011243 Size: 5 KB
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-000921 (34 Act)  Size: 13 KB
2018-02-16 000-22705
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001193125-18-045640 (34 Act)  Size: 33 KB
2018-02-14 000-22705
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001193125-18-045193 (34 Act)  Size: 60 KB
2018-02-14 005-46089
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000080255-18-002288 (34 Act)  Size: 6 KB
2018-02-14 005-46089
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001193125-18-043103 (33 Act)  Size: 55 KB
2018-02-14 333-223020
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001193125-18-042794 (34 Act)  Size: 7 MB
2018-02-13 000-22705
More NBIX SEC Filings

Related news from
Tue, 13 Mar 2018
19:00:00 +0000
Is This AbbVie's Next Blockbuster Drug?
Another positive phase 3 trial may position endometriosis-pain treatment candidate elagolix as a future billion-dollar seller.
Thu, 08 Mar 2018
13:01:54 +0000
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Wed, 07 Mar 2018
18:15:00 +0000
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
SAN DIEGO , March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman , CEO of Neurocrine Biosciences, will present at the following investor conferences: ...
Wed, 21 Feb 2018
13:34:19 +0000
AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug
AbbVie Inc. and Neurocrine Biosciences Inc. shares rose 1.7% and 1.1% respectively in premarket trade Wednesday after the companies announced that their drug met its primary endpoint in a phase 3 trial ...
Wed, 21 Feb 2018
13:00:00 +0000
AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
− First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints − Results demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual ...
Tue, 20 Feb 2018
19:04:00 +0000
5 Stocks to Outperform in 2018’s Volatile Market
TipRanks, which ranks analysts' recommendations, has picked a handful of stocks as safe bets.
Fri, 16 Feb 2018
20:00:00 +0000
NBIX: Will File an NDA for Opicapone in 1H19
On Feb. 14, 2018, Neurocrine Biosciences, Inc. (NBIX) announced the company will file a new drug application (NDA) for opicapone in the first half of 2019 following receipt of the meeting minutes from the January 2018 meeting with the FDA. During that meeting, the FDA did not request that Neurocrine conduct an additional Phase 3 study for opicapone prior to filing the NDA. Opicapone is a peripherally-acting and highly selective inhibitor of catechol-o-methyltransferase (COMT) to be used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors in patients with Parkinson’s disease (PD).
Wed, 14 Feb 2018
21:01:00 +0000
Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data
SAN DIEGO, Feb. 14, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided guidance on the regulatory path forward to support the New Drug Application (NDA) for opicapone, an investigational drug for Parkinson's disease, after receiving meeting minutes from the January 2018 meeting with the FDA. Most importantly, the Neurology Division of the FDA has not requested that Neurocrine conduct an additional Phase III study for opicapone prior to the NDA filing.
Wed, 14 Feb 2018
15:11:27 +0000
Edited Transcript of NBIX earnings conference call or presentation 13-Feb-18 10:00pm GMT
Q4 2017 Neurocrine Biosciences Inc Earnings Call
Tue, 13 Feb 2018
21:17:25 +0000
Neurocrine misses 4Q profit forecasts
The San Diego-based company said it had profit of 7 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings ...
Tue, 13 Feb 2018
21:01:00 +0000
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch ...
Tue, 13 Feb 2018
17:30:00 +0000
Neurocrine Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 13, 2018, at 5:00 ...
Thu, 08 Feb 2018
18:15:00 +0000
Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Live Audio Webcast Will be on February 15, 2018 SAN DIEGO , Feb. 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Leerink Partners 7 th Annual Global Healthcare Conference ...
Thu, 08 Feb 2018
00:15:01 +0000
Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $8.5 million of Shares
CEO of Neurocrine Biosciences Inc (NASDAQ:NBIX) Kevin Charles Gorman sold 105,983 shares of NBIX on 02/06/2018 at an average price of $80.25 a share.
Tue, 06 Feb 2018
18:15:00 +0000
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results
Conference Call and Webcast Scheduled for Tuesday, February 13 SAN DIEGO , Feb. 6, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and ...
Fri, 02 Feb 2018
14:03:31 +0000
Comparing Cara Therapeutics’ Financial Performance
What's in Store for Cara Therapeutics in 2018?
Fri, 02 Feb 2018
12:36:58 +0000
Cara Therapeutics’ Collaboration Agreements
What's in Store for Cara Therapeutics in 2018?
Thu, 01 Feb 2018
21:15:02 +0000
An Insight into Cara Therapeutics’ Drug Pipeline
Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.
Thu, 01 Feb 2018
19:41:22 +0000
Analysts’ Recommendations for Cara Therapeutics in January 2018
Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards